August 2025 in “Frontiers in Pharmacology” [6]-Gingerdiol 3-monoacetate shows promise for treating T. whipplei infections.
Tridax procumbens may boost the immune system.
The combined treatment of Finasteride and Doxazosin affects prostate tissue by reducing cell growth and altering hormone levels.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
3 citations
,
December 1994 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Oral itraconazole effectively reaches and treats deep skin layers in guinea pigs.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
22 citations
,
February 2023 in “European Journal of Neurology” Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” The use of Diane-35 and its generics significantly decreased in the Netherlands.
January 2005 in “Metas de Enfermería” Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
September 2023 in “Journal of the American Academy of Dermatology” 34 citations
,
January 2023 in “Therapeutic Advances in Medical Oncology” Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.
3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
26 citations
,
January 2014 in “ALTEX” Pesticides can cause reproductive and adrenal health issues.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
April 2023 in “Medicina Clínica (english Edition)” August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
26 citations
,
October 2020 in “Pediatric Dermatology” Oral tofacitinib may effectively treat hair loss in children with alopecia areata.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
June 2019 in “Reactions Weekly” 3 citations
,
November 2019 in “Journal of dermatology” Itraconazole effectively treated a woman's painful skin condition and hair loss.
July 2026 in “Journal of the American Academy of Dermatology” Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.